Skip to main content
OTCMKTS:BOPH

Bohai Pharmaceuticals Group Competitors

$0.0010
0.00 (0.00 %)
(As of 03/11/2019)
Add
Compare
Today's Range
$0.00
$0.00
50-Day Range N/A
52-Week Range
$0.00
$0.00
Volume50,000 shs
Average Volume30,425 shs
Market Capitalization$19,520.00
P/E RatioN/A
Dividend YieldN/A
Beta1.78

Competitors

Bohai Pharmaceuticals Group (OTCMKTS:BOPH) Vs. ALSE, ACUS, AFFY, ARYX, AHROQ, and CBPI

Should you be buying BOPH stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Bohai Pharmaceuticals Group, including Alseres Pharmaceuticals (ALSE), Acusphere (ACUS), Affymax (AFFY), ARYx Therapeutics (ARYX), AtheroNova (AHROQ), and China Botanic Pharmaceutical (CBPI).

Bohai Pharmaceuticals Group (OTCMKTS:BOPH) and Alseres Pharmaceuticals (OTCMKTS:ALSE) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

Risk and Volatility

Bohai Pharmaceuticals Group has a beta of 1.78, indicating that its share price is 78% more volatile than the S&P 500. Comparatively, Alseres Pharmaceuticals has a beta of -0.06, indicating that its share price is 106% less volatile than the S&P 500.

Profitability

This table compares Bohai Pharmaceuticals Group and Alseres Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bohai Pharmaceuticals GroupN/AN/AN/A
Alseres PharmaceuticalsN/AN/AN/A

Valuation & Earnings

This table compares Bohai Pharmaceuticals Group and Alseres Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bohai Pharmaceuticals GroupN/AN/AN/AN/AN/A
Alseres PharmaceuticalsN/AN/AN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings and price targets for Bohai Pharmaceuticals Group and Alseres Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bohai Pharmaceuticals Group0000N/A
Alseres Pharmaceuticals0000N/A

Summary

Bohai Pharmaceuticals Group beats Alseres Pharmaceuticals on 1 of the 1 factors compared between the two stocks.

Acusphere (OTCMKTS:ACUS) and Bohai Pharmaceuticals Group (OTCMKTS:BOPH) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, profitability, institutional ownership and dividends.

Risk and Volatility

Acusphere has a beta of -0.25, indicating that its stock price is 125% less volatile than the S&P 500. Comparatively, Bohai Pharmaceuticals Group has a beta of 1.78, indicating that its stock price is 78% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and price targets for Acusphere and Bohai Pharmaceuticals Group, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Acusphere0000N/A
Bohai Pharmaceuticals Group0000N/A

Profitability

This table compares Acusphere and Bohai Pharmaceuticals Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AcusphereN/AN/AN/A
Bohai Pharmaceuticals GroupN/AN/AN/A

Earnings & Valuation

This table compares Acusphere and Bohai Pharmaceuticals Group's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AcusphereN/AN/AN/AN/AN/A
Bohai Pharmaceuticals GroupN/AN/AN/AN/AN/A

Summary

Bohai Pharmaceuticals Group beats Acusphere on 1 of the 1 factors compared between the two stocks.

Bohai Pharmaceuticals Group (OTCMKTS:BOPH) and Affymax (OTCMKTS:AFFY) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, valuation and profitability.

Valuation & Earnings

This table compares Bohai Pharmaceuticals Group and Affymax's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bohai Pharmaceuticals GroupN/AN/AN/AN/AN/A
AffymaxN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings and target prices for Bohai Pharmaceuticals Group and Affymax, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bohai Pharmaceuticals Group0000N/A
Affymax0000N/A

Profitability

This table compares Bohai Pharmaceuticals Group and Affymax's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bohai Pharmaceuticals GroupN/AN/AN/A
AffymaxN/AN/AN/A

Volatility and Risk

Bohai Pharmaceuticals Group has a beta of 1.78, meaning that its stock price is 78% more volatile than the S&P 500. Comparatively, Affymax has a beta of 2.77, meaning that its stock price is 177% more volatile than the S&P 500.

Summary

Affymax beats Bohai Pharmaceuticals Group on 1 of the 1 factors compared between the two stocks.

ARYx Therapeutics (OTCMKTS:ARYX) and Bohai Pharmaceuticals Group (OTCMKTS:BOPH) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

Analyst Ratings

This is a summary of recent recommendations and price targets for ARYx Therapeutics and Bohai Pharmaceuticals Group, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ARYx Therapeutics0000N/A
Bohai Pharmaceuticals Group0000N/A

Profitability

This table compares ARYx Therapeutics and Bohai Pharmaceuticals Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ARYx TherapeuticsN/AN/AN/A
Bohai Pharmaceuticals GroupN/AN/AN/A

Risk and Volatility

ARYx Therapeutics has a beta of -0.53, meaning that its share price is 153% less volatile than the S&P 500. Comparatively, Bohai Pharmaceuticals Group has a beta of 1.78, meaning that its share price is 78% more volatile than the S&P 500.

Valuation and Earnings

This table compares ARYx Therapeutics and Bohai Pharmaceuticals Group's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ARYx TherapeuticsN/AN/AN/AN/AN/A
Bohai Pharmaceuticals GroupN/AN/AN/AN/AN/A

Summary

Bohai Pharmaceuticals Group beats ARYx Therapeutics on 1 of the 1 factors compared between the two stocks.

Bohai Pharmaceuticals Group (OTCMKTS:BOPH) and AtheroNova (OTCMKTS:AHROQ) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.

Profitability

This table compares Bohai Pharmaceuticals Group and AtheroNova's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bohai Pharmaceuticals GroupN/AN/AN/A
AtheroNovaN/AN/AN/A

Analyst Recommendations

This is a summary of current ratings for Bohai Pharmaceuticals Group and AtheroNova, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bohai Pharmaceuticals Group0000N/A
AtheroNova0000N/A

Volatility and Risk

Bohai Pharmaceuticals Group has a beta of 1.78, suggesting that its stock price is 78% more volatile than the S&P 500. Comparatively, AtheroNova has a beta of -8.71, suggesting that its stock price is 971% less volatile than the S&P 500.

Earnings & Valuation

This table compares Bohai Pharmaceuticals Group and AtheroNova's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bohai Pharmaceuticals GroupN/AN/AN/AN/AN/A
AtheroNovaN/AN/AN/AN/AN/A

Summary

Bohai Pharmaceuticals Group beats AtheroNova on 1 of the 1 factors compared between the two stocks.

China Botanic Pharmaceutical (OTCMKTS:CBPI) and Bohai Pharmaceuticals Group (OTCMKTS:BOPH) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.

Profitability

This table compares China Botanic Pharmaceutical and Bohai Pharmaceuticals Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
China Botanic PharmaceuticalN/AN/AN/A
Bohai Pharmaceuticals GroupN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings for China Botanic Pharmaceutical and Bohai Pharmaceuticals Group, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
China Botanic Pharmaceutical0000N/A
Bohai Pharmaceuticals Group0000N/A

Risk and Volatility

China Botanic Pharmaceutical has a beta of 17.09, suggesting that its stock price is 1,609% more volatile than the S&P 500. Comparatively, Bohai Pharmaceuticals Group has a beta of 1.78, suggesting that its stock price is 78% more volatile than the S&P 500.

Valuation and Earnings

This table compares China Botanic Pharmaceutical and Bohai Pharmaceuticals Group's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
China Botanic PharmaceuticalN/AN/AN/AN/AN/A
Bohai Pharmaceuticals GroupN/AN/AN/AN/AN/A

Summary

China Botanic Pharmaceutical beats Bohai Pharmaceuticals Group on 1 of the 1 factors compared between the two stocks.


Bohai Pharmaceuticals Group Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
ALSE
Alseres Pharmaceuticals
0.0$6.00flat$36,000.00N/A0.00
Acusphere logo
ACUS
Acusphere
0.0$0.05flat$0.00N/A0.00Gap Up
Affymax logo
AFFY
Affymax
0.6$0.08flat$0.00N/A0.00Gap Down
ARYX
ARYx Therapeutics
0.0$0.01flat$0.00N/A0.00
AHROQ
AtheroNova
0.0$0.01flat$0.00N/A0.00
CBPI
China Botanic Pharmaceutical
0.0$0.08flat$0.00N/A0.00Gap Down
China Dongsheng International logo
CDSG
China Dongsheng International
0.3$0.05flat$0.00N/A0.00Gap Down
China Health Industries logo
CHHE
China Health Industries
0.4$0.25flat$0.00$9.93 million4.20Upcoming Earnings
DDXSQ
Diadexus
0.0$0.00flat$0.00N/A0.00
ERBA
ERBA Diagnostics
0.8$0.04flat$0.00N/A0.00
FTCY
Global Future City
0.5$0.00flat$0.00N/A0.00Gap Down
GLSI
Greenwich LifeSciences
2.0$32.89flat$0.00N/A0.00
HRBR
Harbor Diversified
0.0$1.90flat$0.00$263.61 million0.00Gap Up
IPAH
Interpharm
0.2$0.00flat$0.00N/A0.00
IRBS
IR Biosciences
0.0$0.00flat$0.00N/A0.00
MBVXQ
MabVax Therapeutics
0.0$0.02flat$0.00N/A0.00Gap Down
MYRX
Myrexis
0.5$0.05flat$0.00N/A0.00Gap Down
NNBP
Nanobac Pharmaceuticals
0.0$0.00flat$0.00N/A0.00Gap Down
PARD
Poniard Pharmaceuticals
0.5$0.09flat$0.00N/A0.00
SGTI
Shengtai Pharmaceutical
0.2$0.02flat$0.00N/A0.00
SKBI
Skystar Bio-Pharmaceutical
0.5$0.00flat$0.00N/A0.00
SUWN
Sunwin Stevia International
0.5$0.05flat$0.00$26.09 million0.00Gap Up
Sycamore Entertainment Group logo
SEGI
Sycamore Entertainment Group
0.3$0.03flat$0.00N/A0.00
SYNI
Synvista Therapeutics
0.0$0.00flat$0.00N/A0.00
TPIY
Tianyin Pharmaceutical
0.6$0.00flat$0.00N/A0.00High Trading Volume
Tibet Pharmaceuticals logo
TBET
Tibet Pharmaceuticals
0.0$0.01flat$0.00N/A0.00High Trading Volume
Gap Down
VOQP
VioQuest Pharmaceuticals
0.0$0.01flat$0.00N/A0.00
This page was last updated on 5/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.